HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Cullinan Therapeutics (NASDAQ: CGEM) and maintained a price target of $35 for the stock. No additional financial figures or strategic changes were mentioned in the article.